Cargando…
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Autores principales: | Thura, Min, Al-Aidaroos, Abdul Qader, Gupta, Abhishek, Chee, Cheng Ean, Lee, Soo Chin, Hui, Kam Man, Li, Jie, Guan, Yeoh Khay, Yong, Wei Peng, So, Jimmy, Chng, Wee Joo, Ng, Chin Hin, Zhou, Jianbiao, Wang, Ling Zhi, Yuen, John Shyi Peng, Ho, Henry Sun Sien, Yi, Sim Mei, Chiong, Edmund, Choo, Su Pin, Ngeow, Joanne, Ng, Matthew Chau Hsien, Chua, Clarinda, Yeo, Eugene Shen Ann, Tan, Iain Bee Huat, Sng, Joel Xuan En, Tan, Nicholas Yan Zhi, Thiery, Jean Paul, Goh, Boon Cher, Zeng, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564534/ https://www.ncbi.nlm.nih.gov/pubmed/34728638 http://dx.doi.org/10.1038/s41467-021-26548-6 |
Ejemplares similares
-
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019) -
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
por: Chee, Cheng E., et al.
Publicado: (2023) -
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
por: Loh, Amos Hong Pheng, et al.
Publicado: (2023)